Abstract
We describe the case of a 64-year-old female patient with rheumatoid arthritis (RA), who presented with lymphoproliferative disease (LPD) soon after the administration of etanercept, and regressed very shortly after the withdrawal of it. The occurrence was also associated with the Epstein–Barr virus (EBV) infection. The case of our patient may provide the evidence that etanercept plays an etiologic role in LPD in patients with RA.
This is a preview of subscription content, log in via an institution to check access.
References
Ekbom A (2005) Epidemiology of lymphoma development in patients with rheumatoid arthritis. Semin Arthritis Rheum 34:28–30
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254–261
Baecklund E, Iliadou A, Askling J (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701
Hoshida Y, Xu JX, Fujita S (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Geborek P, Bladstrom A, Turesson C (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703
Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439
Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740–1751
Miyazaki T, Fujimaki K, Shirasugi Y (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein–Barr virus infection. Am J Hematol (in press)
Starkebaum G (2007) Rheumatoid arthritis and lymphoma: risky business for B cells. J Rheumatol 34:243–246
Thonhofer R, Gaugg M, Kriessmayr M, Neumann HJ, Erlacher L (2005) Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 64:1098–1099
Quartuccio L, De Re V, Fabris M (2006) Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 91:691–694
Okano M, Gross TG (2000) A review of Epstein–Barr virus infection in patients with immunodeficiency disorders. Am J Med Sci 319:392–396
Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 311:1471–1475
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, SH., Kim, CG., Kim, JY. et al. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 28, 475–477 (2008). https://doi.org/10.1007/s00296-007-0467-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-007-0467-6